StartsidaBHC • NYSE
add
Bausch Health Companies Inc
Föregående stängning
7,88 $
Dygnsintervall
7,45 $ - 7,80 $
Årsintervall
3,96 $ - 11,46 $
Börsvärde
2,74 md USD
Genomsnittlig volym
1,27 mn
P/E-tal
-
Direktavkastning
-
Aktuellt
Ekonomi
Resultaträkning
Intäkter
Nettoinkomst
(USD) | sep. 2024info | Förändring Y/Y |
---|---|---|
Intäkter | 2,51 md | 12,15 % |
Rörliga kostnader | 1,27 md | 13,29 % |
Nettoinkomst | −85,00 mn | 77,51 % |
Nettovinstmarginal | −3,39 | 79,93 % |
Vinst per aktie | 1,12 | 9,34 % |
EBITDA | 866,00 mn | 8,93 % |
Giltig skattesats | −338,10 % | — |
Balansräkning
Totala tillgångar
Totala ansvarsskyldigheter
(USD) | sep. 2024info | Förändring Y/Y |
---|---|---|
Kontanta och kortsiktiga investeringar | 719,00 mn | −5,39 % |
Totala tillgångar | 26,54 md | −1,94 % |
Totala ansvarsskyldigheter | 26,78 md | −1,89 % |
Totala tillgångar | −242,00 mn | — |
Utestående aktier | 367,80 mn | — |
P/B | −2,47 | — |
Avkastning på tillgångar | 5,13 % | — |
Avkastning på kapital | 6,37 % | — |
Kassaflöde
Förändring i nettokassa
(USD) | sep. 2024info | Förändring Y/Y |
---|---|---|
Nettoinkomst | −85,00 mn | 77,51 % |
Kontanter från verksamhet | 405,00 mn | 43,62 % |
Kontanter från investering | −102,00 mn | 94,60 % |
Kontanter från finansiering | −189,00 mn | −110,41 % |
Förändring i nettokassa | 127,00 mn | −33,85 % |
Fritt kassaflöde | 606,75 mn | 261,43 % |
Om
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
Grundades
1959
Huvudkontor
Hemsida
Anställda
20 270